Upadacitinib for Management of Alopecia Areata and Rheumatoid Arthritis: Letter to the Editor

A 54-year-old woman with a long history of rheumatoid arthritis (RA) and alopecia areata (AA) showed significant improvement in both conditions after starting treatment with upadacitinib, a selective Janus kinase (JAK) 1 inhibitor. Despite previous treatments, including methotrexate and etanercept, her AA persisted. Upon switching to upadacitinib at 15 mg daily, her RA activity decreased significantly within 3 months, and her hair regrew completely after 6 months, with no side effects observed. This case supports the potential effectiveness of upadacitinib for treating AA in patients with RA.